Medidata Opens Access to its Patient Insights Program, Enabling Sponsors and CROs to Leverage Proprietary Patient Centricity by Design Process for Clinical Trials

Medidata , a Dassault Systmes company, today announced it is allowing sponsors, CROs (contract research organizations), and sites to leverage its proprietary Patient Centricity by Design process for clinical trials.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, February 15, 2022
Information
Tags: 
Biotechnology, Health, Other Health, Program, Patient, Learning, Design, Risk, IMPACT, Cros, Euronext Paris, Hope, Clinical trial, SIMULIA, DELMIA, CATIA, Dassault Group, Patient engagement in Canada, 3D, Research, SOLIDWORKS, McKinney–Vento Homeless Assistance Act, Pharmaceutical industry, Medical device, GEOVIA, ENOVIA, Medidata Solutions, BIOVIA, Compass, Medidata, Dassault Systèmes, MEDIDATA, DASSAULT SYSTèMES
Geotags: 
UNITED STATES, NORTH AMERICA, NEW YORK, NEW YORK CITY
⚠ generated by AI ↴
Summary
Key Points: 
  • Medidata , a Dassault Systmes company, today announced it is allowing sponsors, CROs (contract research organizations), and sites to leverage its proprietary Patient Centricity by Design process for clinical trials.
  • Medidata will open access to its Patient Insights Program as part of a new offering to incorporate a patient-centric approach to the design and development of clinical trial protocols and technologies.
  • We are opening up access to this program to ultimately make clinical trials an option for more people, including those historically left behind by clinical trials.
  • The Medidata Patient Insights team has run over 20 design studios to provide feedback and insights into Medidata's products.


Medidata, a Dassault Systèmes company, today announced it is allowing sponsors, CROs (contract research organizations), and sites to leverage its proprietary Patient Centricity by Design process for clinical trials. Medidata will open access to its Patient Insights Program as part of a new offering to incorporate a patient-centric approach to the design and development of clinical trial protocols and technologies.

The Patient Insights Program provides access to Medidata’s experienced and diverse Patient Insights Board, using innovative workshops called design studios to guide the creation of protocols and patient-facing solutions to improve clinical trial experiences, expedite clinical trial delivery timelines, and bring therapies to market faster.

“Medidata is the first company to institute a formal process of infusing the patient perspective into the software development life cycle to create technical solutions improving the overall patient experience,” said Alicia Staley, vice president, Patient Engagement at Medidata. “We are opening up access to this program to ultimately make clinical trials an option for more people, including those historically left behind by clinical trials.”

“Patient centricity” has been a buzzword for nearly a decade but most clinical studies are designed with little to no direct input from the patients/caregivers that are expected to enroll in and adhere to a clinical research study. Patient engagement has mostly been limited to sporadic and superficial sessions, with little impact on reducing patient burden or improving enrollment, retention, and experience.

“Participating in a Patient Design Studio with Medidata's patient advocates to co-create, edit and inform our Clinical Trial Readiness Tool was invaluable,” said Erin Miller, development manager/ IMPACT and PATH Program liaison for Lazarex Cancer Foundation. “This one-of-a-kind tool will help us understand each patient’s individual journey and allow us to get them the resources they need to successfully stay in their clinical trial, giving them hope and a chance for an improved cancer health outcome.”

The Medidata Patient Insights team has run over 20 design studios to provide feedback and insights into Medidata's products. Medidata’s Patient Centricity by Design is a formal methodology by which the patient perspective is infused into the software development life cycle. This video shows how Medidata develops empathetic technical solutions by including patients in our work.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,900+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Copyright: 
Copyright Business Wire 2022